Michael Halstead News Today

AdvisorShares Investments LLC lowered its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 28.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,151 shares of the biopharmaceutical company’s stock after selling 1,621 shares during the period. AdvisorShares Investments LLC’s holdings in Intra-Cellular Therapies were worth $297,000 at the end of the […]

Sectoral Asset Management Inc. cut its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 94.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,420 shares of the biopharmaceutical company’s stock after selling 116,260 shares during the period. Sectoral Asset Management Inc.’s holdings […]

Mach 1 Financial Group LLC bought a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 7,180 shares of the biopharmaceutical company’s stock, valued at approximately $514,000. A number of […]

Several analysts have recently updated their ratings and price targets for Intra-Cellular Therapies (NASDAQ: ITCI): 4/24/2024 – Intra-Cellular Therapies had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock. 4/23/2024 – Intra-Cellular Therapies had its price target raised by analysts at Canaccord Genuity Group Inc. […]

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 36.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 18,738 shares of the biopharmaceutical company’s stock after acquiring an additional 4,974 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s […]

Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) had its price objective boosted by Canaccord Genuity Group from $100.00 to $107.00 in a report released on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Other research analysts have also issued research reports about the company. Robert W. Baird increased […]

China Universal Asset Management Co. Ltd. grew its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 351.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,133 shares of the biopharmaceutical company’s stock after acquiring an additional 8,668 shares during the […]

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have received a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year […]

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) EVP Michael Halstead sold 7,345 shares of Intra-Cellular Therapies stock in a transaction on Monday, March 11th. The stock was sold at an average price of $65.97, for a total value of $484,549.65. Following the sale, the executive vice president now owns 19,803 shares in the company, […]

Polar Capital Holdings Plc lifted its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 150.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,000,000 shares of the biopharmaceutical company’s stock after purchasing an additional 600,000 shares during the quarter. Polar Capital Holdings […]